FDA advisory committee closes door to single-arm trial of PI3K inhibitors
- Probiotics may promote tumor progression?
- Taiwan Professor: Big data confirms that the COVID-19 vaccine is ineffective
- Why are the majority of Monkeypox infected people who have sex with men (MSM)?
- Experimental treatment improves skin cancer survival by 25%
- People who get flu vaccine are 40% less likely to develop Alzheimer’s disease
- Depriving women of the right to abortion is a setback for medical health and society
FDA advisory committee closes door to single-arm trial of PI3K inhibitors
- How long can the patient live after heart stent surgery?
- More than 500 new drugs for blood diseases are in development
- Keytruda: The 5-year survival rate for advanced lung cancer doubled!
- Amylyx released the latest statistical analysis of new ALS drugs after being opposed by FDA panel last month
- Celine Dion is paralyzed due to muscle cramps: What are Muscle Cramps?
- Taiwan death from COVID-19 vaccination exceeds death from COVID-19
- The world top 5 best-selling drugs in 2020
FDA advisory committee closes door to single-arm trial of PI3K inhibitors.
April 21, 2022, 16 in favor, 0 against, 1 abstention – FDA Oncology Drugs Advisory Committee (ODAC) Support: Future approval of PI3K inhibitors should be based on randomized data rather than single-arm trials.
So far, the FDA has approved 4 PI3K inhibitors for the treatment of hematological malignancies based on single-arm data, namely: idelalisib (Zydelig), copanlisib (Aliqopa), duvelisib (Copiktra), umbralisib (Ukoniq), Ukoniq has recently Withdrawal from the market (note: failed to show OS benefit based on UNITY-CLL trial results).
All 4 drugs showed improvement in ORR or PFS. However, the results of 6 post-marketing randomized controlled trials have shown that OS may be compromised, and serious and fatal adverse reactions may occur.
One of the committee members, Dr. Christopher Lieu, from the University of Colorado Cancer Center, said: “Achieving an OS endpoint for an indolent cancer is costly and time-consuming, and if there are likely to be significant adverse effects at the time of treatment, PFS is a regulatory-approved endpoint. End point, it may not be reasonable.”
“Companies have an obligation to demonstrate that their products are safe and effective,” the FDA said at the hearing. “These products are not adequately supported based on estimated OS, prior data information, observed toxicity profiles, and questionable dose selection. is a safe conclusion.”
Dr. Lieu concluded: “Based on the data available, we would like to see a trend in OS benefit. Bottom line: if we don’t extend patients’ lives with any treatment, we expose them to toxicity and reduce their quality of life. , are we really helping patients? I don’t believe it.”
(source:internet, reference only)
Disclaimer of medicaltrend.org
